An interventional study of Early time restricted eating and Late time restricted eating in Obesity, Non-Alcoholic Fatty Liver Disease and Insulin Resistance, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-29.
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Obesity with a site in Netherlands — 43 open to participants now, 55 under way, 14 of them phase 3. Obesity · Netherlands.
Among the 248 studies in Obesity with a site in Netherlands, this one is the 150th largest by planned enrollment of the 211 interventional ones that give a count, is one of 11 that started in 2023, is one of 128 with no phase, reaches primary completion later than 29 of the 54 other live ones, and was the 196th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →43 of the 248 studies in Obesity with a site in Netherlands are open now. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18+
Novo Nordisk A/S · Sites in Netherlands, United States, Belgium and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Netherlands, Denmark
Ages 18+
Novo Nordisk A/S · Sites in Netherlands
Ages 18–65 · Healthy volunteers
Novo Nordisk A/S · Sites in Netherlands, United States, Argentina and 16 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 38 · Phase 4 13
First in 2001; this study’s year is marked. 11 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 58 across the 211 interventional studies, 132 across the 37 observational. Of the 170 that completed or were terminated, 21 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 248 have an industry lead sponsor. The 10 most frequent:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 533 studies on the registry; 182 are open to participants now.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) has 9 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
19 of the studies in Obesity with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07463196AC Immune SAA Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors | 2026-12 |
| NCT06982131Hoffmann-La RocheA Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants | 2026-12-07 |
| NCT06137261Franciscus GasthuisScreening Adults With Obesity to Reduce Heart Failure Events | 2026-12-08 |
| NCT05359887University Medical Center GroningenPET-study on the Role of the Reward System in Weight Loss After Bariatric Surgery | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 248 studies in Obesity with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
We aim to determine the effect of combined isocaloric time restricted eating and meal timing on metabolic health, liver fat, functional brain networks, inflammation, and sleep pattern/quality in subjects with obesity and insulin resistance.
Obesity is an alarming global health issue, with increasing prevalence. Obesity leads to a vast array of disorders, including dyslipidemia, the accumulation of intrahepatic triglycerides (IHTG), multiorgan insulin resistance and type 2 diabetes mellitus. In addition, disruption of the circadian rhythm (circadian misalignment), which is associated with irregular eating schedules, is an important risk factor for the development of obesity, IHTG and type 2 diabetes mellitus. Time restricted eating (TRE) is a form of intermittent fasting, in which the daily eating period is restricted. The beneficial effect of this type of diet might relate to adequate synchronization of food intake and fasting to the internal rhythm of the circadian tissue clocks, improving metabolic handling of nutrients and metabolic flexibility.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* 50% of daily calories at breakfast, 35% at lunch and 15% at dinner. 85% of calories consumed in 6h, i.e., between 7AM and 1PM. * Eating period, 10h (7AM-5PM); fasting period, 14h; Breakfast between 7 and 8 AM; lunch between 12 AM and 1 PM; dinner between 4 and 5 PM.
Behavioral: Early time restricted eating
* 15% of daily calories at breakfast, 35% at lunch and 50% at dinner. 85% of calories consumed in 6h, i.e., between 2PM and 8PM. * Eating period, 10h (10AM-8PM), fasting period, 14h; Breakfast between 10 and 11 AM; lunch between 2 and 3 PM; dinner between 7 and 8 PM.
Behavioral: Late time restricted eating
Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM
Also known as: early-TRE
Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM
Also known as: late-TRE
Insulin Sensitivity
We will use the Oral Minimal Model Method in conjunction with a Mixed Meal Tolerance Test (MMTT) to quantitatively evaluate insulin sensitivity. Concentrations of insulin, glucose, and C-peptide will be measured during the course of the MMTT to serve as the requisite inputs for the model. The output is in dl/kg/min/uU/ml.
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Change in plasma insulin
Fasted and stimulated insulin (pmol/L) will be measured during MMTT
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Change in plasma glucose
Fasted and stimulated glucose (mmol/L) will be measured during MMTT
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Change in intrahepatic fat
To quantify the intrahepatic fat content, a single voxel 1H-MRS (magnetic resonance spectroscopy) will be used. Relative fat content will be expressed as the ratio of the fat peak over the cumulative fat and water peak. This will also be corrected for T2 relaxation.
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Change in beta cell function (C-peptide)
Fasted and stimulated C-peptide (nmol/L) will be measured during MMTT
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Change in insulin aignaling
Biopsies will be taken from skeletal muscle and subcutaneous fat to measure key proteins in the insulin signalling pathway (Western blots)
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Change in glucose variability
In our study, we will deploy Continuous Glucose Monitors (CGMs) to acquire an in-depth understanding of glucose variability in participants throughout the course of the intervention. These monitors gauge glucose concentrations in the interstitial fluid (mmol/L), serving as a reliable proxy for blood glucose levels. This approach will enable us to assess key metrics such as mean, minimum and maximum glucose levels.
Time frame: Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2
De novo lipogenesis
Fasted and stimulated de novo lipogenesis (DNL) will be measured during the MMT as 2H incorporation into fatty acids following deuterated water (2H2O) administration
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Immunological markers
We will conduct immune cell phenotyping on whole blood samples to identify and categorize various immune cell types. Additionally, we will assess immune cell function and metabolism in isolated peripheral blood mononuclear cells (PBMCs). Inflammatory markers will also be assessed in serum samples to provide a comprehensive overview of immune and inflammatory status.
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Physical activity
Physical activity will be assessed via accelerometry. Accelerometry represents the magnitude of acceleration in any direction, over a predefined epoch.
Time frame: Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2
Functional brain activity
Brain activation maps and functional connectivity will be assessed by blood oxygen dependent signals in the resting state and after visual food cues using functional magnetic resonance imaging (fMRI).
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Psychological factor - Food Craving
We will use the General Food Cravings Questionnaire (G-FCQ) to evaluate the frequency and intensity of food cravings among participants. The scoring for the G-FCQ ranges between 21 and 105, with higher scores indicative of more pronounced food craving tendencies.
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Psychological factor - Eating behaviour
We will utilize the Dutch Eating Behavior Questionnaire (NVE) to assess and categorize the eating behaviors and tendencies of our participants. The NVE discerns three distinct eating styles: emotional eating, external eating, and restrained eating. A higher score within a specific style suggests a predominant inclination towards that particular eating behavior.
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Psychological factor - Hunger scale
We will employ a nine-question visual analogue scale (VAS) to assess hunger. Each question will be scored 0-100.
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Psychological factor - Food addiction
We will use the Yale Food Addiction Scale 2.0 (YFAS 2.0) to assess addictive behaviours. The YFAS 2.0 is designed in accordance with the DSM-5 criteria, and its scoring system mirrors the number of DSM-5 criteria fulfilled indicative of addiction.
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Psychological factor - Impulsiveness
We will use the Barratt Impulsiveness Scale (BIS) to scale impulsiveness towards food. This will help us understand how impulsivity might influence dietary behaviour. The score ranges from 30-120 and a higher score leans towards greater impulsivity.
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Psychological factor - Chronotype
To determine natural sleep-wake patterns, we will use the Munich Chronotype Questionnaire (MCTQ). This tool offers a comprehensive understanding of sleep behaviors, revealing a chronotype.
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Subject experience with intervention
We will employ a semi-structured oral interview as part of our qualitative approach to understand our participants' experience and adherence to the intervention.
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Delay discounting computational task
The delay discounting task aids in understanding the decision-making processes that might contribute to overeating and poor food choices. In this task, we will be able to measure the ability of each individual to delay immediate gratification for a greater future reward.
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Iowa gambling computational task
We use the Iowa gambling task to assess decision-making and risk-reward sensitivity. Participants choose cards from four decks, each with different reward and punishment rates, aiming to maximize their winnings. We use this task to study risk taking and impulsive behaviour.
Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2023; primary completion for Dec 2027, 50 months later.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 50 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) →